{
    "clinical_study": {
        "@rank": "63939", 
        "acronym": "IMAGINE 8", 
        "arm_group": [
            {
                "arm_group_label": "Insulin Peglispro", 
                "arm_group_type": "Experimental", 
                "description": "Standard dose of insulin peglispro administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin peglispro administered once, SQ on day 3 of the inpatient stay."
            }, 
            {
                "arm_group_label": "Insulin Glargine", 
                "arm_group_type": "Experimental", 
                "description": "Standard dose of insulin glargine administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin glargine administered once, SQ on day 3 of the inpatient stay."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to compare the effect of double doses of a study drug\n      known as insulin peglispro and insulin glargine in participants who have type 2 diabetes.\n      Participants will be treated for up to 11 weeks, and will take part in two study periods.\n      Each participant will receive insulin peglispro during one treatment period and insulin\n      glargine during the other treatment period."
        }, 
        "brief_title": "A Study to Compare the Effect of Double Doses of Long-acting Insulin Therapies in Participants With Type 2 Diabetes", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have type 2 diabetes mellitus (T2DM), based on the World Health Organization (WHO)\n             classification, for \u22651 year.\n\n          -  Use any type of basal insulin (except degludec), including once-or twice-daily human\n             insulin neutral protamine Hagedom (NPH), insulin detemir, or insulin glargine.\n\n          -  Have hemoglobin A1c (HbA1c) levels \u22649.0% according to central laboratory testing at\n             screening.\n\n          -  Have body mass index (BMI) \u226440.0 kilogram/square meter (kg/m^2).\n\n          -  Have been treated with stable doses of insulin for at least 30 days before screening\n             with:\n\n               -  Basal insulin with daily doses \u00b130% of mean during the last 4 weeks.\n\n               -  Doses of a basal insulin must be between 0.3 unit/kg/day and 1 unit/kg/day.\n\n          -  If on metformin, thiazolidinediones (TZDs), sodium glucose co-transporter 2 (SGLT-2)\n             inhibitors, or dipeptidyl peptidase (DPP4) inhibitors, must be on stable doses for\n             the last 30 days.\n\n        Exclusion Criteria:\n\n          -  Are using prandial, self-mixed, or premixed insulin. Participants using prandial\n             insulin may be switched to everyday (qd) glargine if investigator judges that the\n             participant will still meet fasting glucose requirements for randomization.\n\n          -  Are using insulin pump therapy.\n\n          -  Have excessive insulin resistance: Defined as >1.0 unit/kg/day as baseline treatment.\n\n          -  If being treated with sulfonylureas (SUs) before screening, then must have SUs washed\n             out between screening and randomization.\n\n          -  Use any of these concomitant medications: morphine, codeine, antidiuretics,\n             glucagon-like peptide-1 (GLP-1) receptor agonists (for example, exenatide, exenatide\n             once weekly, lixisenatide or liraglutide), or pramlintide, used concurrently or\n             within 90 days before screening.\n\n          -  Have hypoglycemia unawareness, defined as confirmed by laboratory test results or by\n             historical episodes of hypoglycemia <54 mg/dL  (3.0 mmol/L) without symptoms.\n\n          -  Have fasting hypertriglyceridemia >400 mg/dL (>4.5 mmol/L) at screening, as\n             determined by the local laboratory.\n\n          -  Have had any episode of severe hypoglycemia (defined by requiring assistance due to\n             neurologically disabling hypoglycemia) within 6 months before entry into the study.\n\n          -  Have had 2 or more emergency room visits or hospitalizations due to poor glucose\n             control in the past 6 months.\n\n          -  Have had a previous clinically significant episode of ketoacidosis as determined by\n             the investigator (ketone bodies at fasting and without acidosis is acceptable) in the\n             past 6 months.\n\n          -  Have history of renal transplantation, are currently receiving renal dialysis, or\n             have estimated Glomerular Filtration Rate (eGFR) <60 milliliters/minute.\n\n          -  Have obvious clinical signs or symptoms of liver disease (excluding nonalcoholic\n             fatty liver disease), acute or chronic hepatitis, nonalcoholic steatohepatitis, or\n             elevated liver enzyme measurements.\n\n          -  Have active or untreated malignancy, have been in remission from clinically\n             significant malignancy (other than basal cell or squamous cell skin cancer) for less\n             than 5 years, or are at increased risk for developing cancer or a recurrence of\n             cancer in the opinion of the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "67", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132637", 
            "org_study_id": "14288", 
            "secondary_id": [
                "I2R-MC-BIDD", 
                "2012-005174-56"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Insulin Peglispro", 
                "description": "Administered SQ", 
                "intervention_name": "Insulin Peglispro", 
                "intervention_type": "Drug", 
                "other_name": "LY2605541"
            }, 
            {
                "arm_group_label": "Insulin Glargine", 
                "description": "Administered SQ", 
                "intervention_name": "Insulin Glargine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Chula Vista", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Neuss", 
                        "country": "Germany"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Comparison of Pharmacodynamics When Receiving a Double Dose of Insulin Peglispro or Insulin Glargine in Patients With Type 2 Diabetes Mellitus: A Double-Blind, Crossover Design Study", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of Clinically Significant Hypoglycemia", 
            "safety_issue": "Yes", 
            "time_frame": "Predose to 84 Hours Post Double Dose (Day 3 in each period)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132637"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of Hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "Predose to 84 Hours Post Double Dose (Day 3 in each period)"
            }, 
            {
                "measure": "Mean Nadir Glucose", 
                "safety_issue": "Yes", 
                "time_frame": "Predose to 84 Hours Post Double Dose (Day 3 in each period)"
            }, 
            {
                "measure": "Time to the Nadir Glucose", 
                "safety_issue": "Yes", 
                "time_frame": "Predose to 84 Hours Post Double Dose (Day 3 in each period)"
            }, 
            {
                "measure": "Mean Duration in Minutes that Each Participant Spends with Glucose Less than or Equal to 70 Milligrams per Deciliter (mg/dL) (3.9 Millimoles per Liter [mmol/L])", 
                "safety_issue": "Yes", 
                "time_frame": "Predose to 84 Hours Post Double Dose (Day 3 in each period)"
            }, 
            {
                "measure": "Fasting Blood Glucose (FBG)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1, Day 2, Day 3 Following Double Dose (Day 3 in each period)"
            }, 
            {
                "measure": "Pharmacodynamics: Glucose Area Under the Concentration Time Curve (AUC) Prandial", 
                "safety_issue": "No", 
                "time_frame": "Preprandial to 3 Hours Postprandial (Day 2 in each period)"
            }, 
            {
                "measure": "Beta Cell Function", 
                "safety_issue": "No", 
                "time_frame": "0-30 Minutes After Standard Dose (Day 2 in each period)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}